MEDIQON Group AG (CHG) AI Stock Analysis

• Market Cap: €879.78M
• Dividend Yield: N/A
• Average Volume (3M): 26.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: 51.05%
• EPS Growth: -242.58%
• Country: DE
• Employees: 800
• Sector: Technology
• Sector Strength: 88
• Industry: Information Technology Services
• EPS (TTM): -0.69
• Shares Outstanding: 23,842,152
• 10 Day Avg. Volume: 27,625
• 30 Day Avg. Volume: 26,381
• PEG Ratio: -0.40
• Price to Book (P/B): 2.59
• Price to Sales (P/S): 5.28
• P/FCF Ratio: 83.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: €37.00 ▼(-1.60% Downside)

The overall stock score for MEDIQON Group AG is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability challenges. Technical analysis indicates a lack of strong momentum, while valuation is negatively impacted by the company's unprofitability and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, which can lead to increased market share and long-term sustainability.

Cash Flow Generation

Improved cash flow generation enhances liquidity, providing the company with more flexibility to invest in growth opportunities and weather economic downturns.

Leverage Management

Better leverage management reduces financial risk and interest expenses, allowing the company to allocate more resources towards strategic initiatives.

Negative Factors

Profitability Challenges

Ongoing profitability issues can hinder reinvestment in the business and affect long-term competitiveness and shareholder returns.

Decreased Gross Profit Margin

A declining gross profit margin may indicate rising costs or pricing pressure, potentially impacting future profitability and competitive positioning.

Negative Return on Equity

Negative ROE suggests inefficiencies in generating returns from equity investments, which could deter investors seeking growth and profitability.

MEDIQON Group AG Business Overview & Revenue Model

Company Description

MEDIQON Group AG (CHG) is a Swiss-based company specializing in innovative solutions for the healthcare sector, focusing primarily on medical technology and digital health services. The company operates in various sectors including diagnostics, medical devices, and telemedicine, providing a range of products and services designed to enhance patient care and streamline healthcare processes. MEDIQON's core offerings include advanced medical imaging systems, health data management software, and telehealth platforms that connect patients with healthcare professionals.

How the Company Makes Money

MEDIQON Group AG generates revenue through multiple streams, primarily from the sale of medical devices and technology solutions to healthcare providers, hospitals, and clinics. The company also earns income from licensing its proprietary software solutions, which facilitate efficient health data management and patient interaction. Additionally, MEDIQON has established strategic partnerships with other healthcare organizations and technology firms, allowing for collaborative product development and expanded market reach. These partnerships enhance the company's service offerings, driving further revenue through joint ventures and shared technology initiatives.

MEDIQON Group AG Financial Statement Overview

Summary

MEDIQON Group AG is experiencing strong revenue growth, but profitability remains a concern with negative net income and EBIT margins. The balance sheet shows improved leverage, but profitability metrics like ROE are still negative. Cash flow generation is improving, but further analysis is needed to understand cash flow efficiency fully.

Income Statement

MEDIQON Group AG has shown strong revenue growth of 27.02% in the latest year, indicating a positive trajectory. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased significantly from the previous year, suggesting potential challenges in cost management or pricing strategy.

Balance Sheet

The company's debt-to-equity ratio has improved over the years, indicating better leverage management. However, the return on equity remains negative, reflecting ongoing challenges in generating profits from shareholders' equity. The equity ratio is stable, suggesting a balanced capital structure.

Cash Flow

MEDIQON Group AG has achieved positive free cash flow growth, which is a positive sign for liquidity. However, the operating cash flow to net income ratio is not available, limiting insights into cash flow efficiency. The free cash flow to net income ratio is also unavailable, which could provide further clarity on cash generation relative to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	131.62M	110.67M	70.77M	42.07M	28.66M	1.08M
Gross Profit	-2.22M	47.02M	8.38M	6.84M	12.26M	360.69K
EBITDA	1.59M	16.35M	16.14M	4.82M	7.16M	-1.33M
Net Income	-23.07M	-11.47M	-4.08M	-5.88M	-2.27M	-2.27M
Balance Sheet
Total Assets	591.39M	353.74M	223.95M	169.28M	103.55M	49.81M
Cash, Cash Equivalents and Short-Term Investments	52.20M	58.51M	50.84M	26.28M	11.09M	614.04K
Total Debt	200.34M	73.60M	69.35M	62.09M	51.70M	25.00M
Total Liabilities	306.36M	128.75M	99.87M	77.11M	61.71M	41.55M
Stockholders Equity	224.81M	224.99M	126.06M	93.76M	42.57M	10.00M
Cash Flow
Free Cash Flow	10.70M	6.96M	3.81M	3.67M	1.15M	-1.76M
Operating Cash Flow	13.38M	11.47M	7.37M	5.69M	2.87M	-1.76M
Investing Cash Flow	-147.02M	-98.82M	-36.34M	-53.21M	-47.40M	-5.21M
Financing Cash Flow	135.34M	89.00M	48.15M	58.78M	47.06M	7.22M

MEDIQON Group AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 37.60
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:CHG, the sentiment is Positive. The current price of 37.6 is above the 20-day moving average (MA) of 36.95, above the 50-day MA of 36.87, and below the 200-day MA of 38.36, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 54.69 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:CHG.

MEDIQON Group AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GFT	77 Outperform	€485.98M	13.89	13.78%	2.64%	3.28%	-26.16%
D6H	68 Neutral	€569.01M	23.23	15.66%	1.46%	11.88%	-3.36%
NA9	68 Neutral	€961.42M	19.65	24.22%	1.29%	5.63%	-7.19%
COK	65 Neutral	€884.01M	51.15	3.09%	3.64%	-0.61%	-52.28%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
ADN1	56 Neutral	€566.00M	41.70	6.82%	0.87%	12.37%	196.11%
CHG	45 Neutral	€879.78M	-37.99	-12.43%	―	51.05%	-242.58%